TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04843176

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Prototype artificial intelligence algorithm
Description: Developed by the University of Hong Kong

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: LI-RADS
Description: The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
Study: NCT06235216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Dose of 10 mg/kg intravenously
Study: NCT05118854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV
Study: NCT05887830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
Study: NCT06720597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily low-dose PDE5 inhibitor therapy
Description: Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.
Study: NCT06201624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Patients will receive 1mg/kg/day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple combination formula
Description: Patients are instructed to apply the triple combination formula at night daily for 3 months
Study: NCT05085314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ngenuity digital 3D microscope
Description: Cataract surgery under topical anesthesia with the Ngenuity digital 3D microscope, Alcon, Fort Worth, TX

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional microscope
Description: Cataract surgery under topical anesthesia with a conventional microscope
Study: NCT05118854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given by IV
Study: NCT05427279

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolized Collagen
Description: The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PrimaColl
Description: The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
Study: NCT06173778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4mg
Description: Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active medication, self-administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT, nicotine patch)
Description: Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT, nicotine patch)
Description: Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Smoking Cessation Counseling
Description: Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
Study: NCT05307263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy of atherectomy and DCB
Description: The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCB alone
Description: The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
Study: NCT06544993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meso-botox
Description: Micro-Botox, is a highly diluted Botulinum toxin type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meso-botox
Description: Micro-Botox, is a highly diluted Botulinum toxin type A
Study: NCT04497610

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sample
Description: Patient will blow into a tube 5 times.
Study: NCT06173778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Smoking Cessation Counseling
Description: Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
Study: NCT05699759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K8
Description: Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
Study: NCT06305351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833 QD
Description: Both administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833 BID
Description: Both administered orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757 and K-833 QD
Description: Both administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757 and K-833 BID
Description: Both administered orally twice daily
Study: NCT06348355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]savolitinib
Description: Radiopharmaceutical; IMP; Sterile solution for IV injection, not more than 10 μg, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: IMP; 300 mg tablet, oral single administration
Study: NCT05300581

Intervention type: OTHER
Group type: OTHER
Intervention: OPAT for PWID
Description: Observational: Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
Study: NCT06204263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: finger feeding
Description: The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
Study: NCT05333068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI revascularization strategy based on combined FFR and OCT assessment
Description: PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCI revascularization strategy based FFR assessment
Description: PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
Study: NCT06045676

Intervention type: DEVICE
Intervention: ECG
Description: ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.

Intervention type: DEVICE
Intervention: ECG
Description: ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.

Intervention type: DEVICE
Intervention: ECG
Description: ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.

Intervention type: DEVICE
Intervention: ECG
Description: ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.

Intervention type: DEVICE
Intervention: ECG
Description: ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.
Study: NCT05998187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-rectal botulinum toxin injections
Description: Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
Study: NCT05216978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
Study: NCT06385574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy
Description: Conventional hand therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy
Description: Conventional hand therapy
Study: NCT05684991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KMS-66 Ashwagandha 300mg
Description: One capsule is taken by mouth twice daily with water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: One capsule is taken by mouth twice daily with water
Study: NCT06286774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
Study: NCT06577324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live group music therapy
Description: The intervention will involve the use of live music in a group of patients during their quimiotherapy session. The intervention will last approximately forty minutes and will be organized into three stages: Opening (10 min), Body Awareness and Movement (7-10 minutes), Intervention Development (20 minutes). Genres and songs are performed based on the group's preferences and suggestions. The instruments used for the group intervention are the same as those mentioned earlier; participants are provided with percussion instruments, accompanied by the music therapist's voice and the participants' voices. The intervention encourages active participation, with users playing the instruments, singing, engaging in dialogue, and/or reflecting between songs.
Study: NCT05936060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INMUNOCEM
Description: Mesenchymal Stromal Cell suspension intraarticularly injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO COMPARATOR
Description: Administration of plasmalyte as a vehicle for MSC
Study: NCT05890924

Intervention type: OTHER
Intervention: WAST questionnaire
Description: WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)

Intervention type: OTHER
Intervention: WAST questionnaire
Description: WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)
Study: NCT06183307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nattokinase
Description: Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive 1 capsule per day with 100mg containing corn starch for 2 months.
Study: NCT03735277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC, Cord Blood
Description: HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
Study: NCT06369363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be assigned to 1 week of transdermal placebo patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
Study: NCT05780125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FibCLOT
Description: 30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiaSTAP
Description: 30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration
Study: NCT06292741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudoscan
Description: recording of sudomotor function and pupillary reactivity
Study: NCT06720597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone therapy as per clinical guidelines.
Description: Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
Study: NCT05576012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOL-116
Description: Participants will receive SC injection in a double-blind manner

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injection in a double-blind manner
Study: NCT05301361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Oral Solution
Description: The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate Oral Solution
Description: The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
Study: NCT04757961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeStories
Description: The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
Study: NCT06402916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry drink
Description: Blueberry drink equivalent to 240g fresh blueberries.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Drink containing no active ingredient.
Study: NCT04693650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlock UHF stimulation
Description: NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
Study: NCT06551064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FYB206
Description: FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda
Description: Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
Study: NCT05457972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Imvexxy is an FDA-approved drug produced by TherapeuticsMD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Moisturizer
Description: Ingredients include hydrogenated coconut and palm oils and natural-source vitamin E (d-alpha tocopheryl acetate and tocopherols).
Study: NCT06034002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.
Study: NCT05593016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
Description: Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Control Arm
Description: The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer.
Study: NCT05252572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL1 CAR T-cells
Description: Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection